New drug combo aims to outsmart Platinum-Resistant ovarian cancer
NCT ID NCT02595892
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This phase 2 trial tests whether adding an experimental drug called M6620 (berzosertib) to standard gemcitabine chemotherapy helps women with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based treatment. About 70 participants will receive either the combo or gemcitabine alone. The main goal is to see if the combo delays tumor growth longer than standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Berzosertib (M6620) plus gemcitabine
- What this could lead to
- If it works, this combination could slow tumor growth better than standard chemotherapy alone for women with hard-to-treat ovarian cancer.
- What could go wrong
- This is a mid-stage trial with only 70 participants. The added drug may not improve outcomes and could cause more side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN SEROUS TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Hospital in Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UC San Diego Medical Center - Hillcrest
San Diego, California, 92103, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New targeted therapy shows promise for Tough-to-Treat ovarian cancer
- Engineered immune cells target Hard-to-Treat ovarian cancer
- New combo therapy aims to control ovarian cancer and reduce painful fluid buildup